Skip to main navigation
Skip to content
Aerpio Pharmaceuticals
  • Contact Us
  • Careers
  • About Aerpio
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Ophthalmology Advisory Boards
  • Technology
    • Tie2 Pathway – The Basics
    • VE-PTP and Angpt2
    • Aerpio’s Tie2 Activators
  • Pipeline
    • Razuprotafib (AKB-9778) Open Angle Glaucoma
    • Razuprotafib (AKB-9778) Diabetic Nephropathy
    • ARP-1536 Diabetic Retinopathy/Nephropathy
    • Bispecific Ab Retinopathy/Cancer
    • GB004/AKB-4924 IBD
  • Therapeutic Areas
    • Open Angle Glaucoma
    • Diabetic Nephropathy
    • Retinopathy (Wet AMD/DME)
    • Cancer
    • IBD
  • Partnering
  • Investors
  • Publications
Aerpio Pharmaceuticals

Breadcrumb

  • Home >>
  • Investors >>
  • News releases >>
  • Aerpio pharmaceuticals commences trading otcqbr market >>

Press Release

View printer-friendly version
<< Back
Aerpio Pharmaceuticals Commences Trading on the OTCQB® Market
Aerpio Pharmaceuticals Commences Trading on the OTCQB Market Exchange.pdf 464.6 KB

Shareholder Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
  • IR Contacts

Investor Relations

  • Investor Overview
  • Stock Information
    • Stock Quote & Chart
  • Press Releases
  • Events & Presentations
    • Upcoming Events
    • Archived Events
    • Presentations
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
  • Corporate Governance
    • Governance Highlights
    • Committee Composition
  • Investor Resources
    • Investor FAQ
    • Information Request
    • E-mail Alerts
    • IR Contacts

© 2020 Aerpio

  • Site Map
  • Terms of Use
  • Privacy Policy
Website by Axxiem